Thyme Care raises $125 million, pushing cancer care startup's valuation above $2 billion
Thyme Care has raised $125 million from investors in a deal doubling the cancer startup's valuation as it tackles critical disease treatment gaps.
Thyme Care has raised $125 million from investors in a deal doubling the cancer startup's valuation as it tackles critical disease treatment gaps. This story matters for Finance & Markets readers tracking fund. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. FundNews curates and briefs the finance & markets stories that matter. Our editorial policy →